Compugen Highlights COM701 Ovarian Trial, Expands AI Platform Into Tumor TargetsDefense World · Oct 6, 2026
Compugen to Participate in a Fireside Chat at the H.C. Wainwright 3rd Annual AI Based Drug Discovery & Development ConferencePRNewsWire · Oct 6, 2026
Compugen Highlights COM701 Ovarian Trial, Expands AI Platform Into Tumor TargetsMarketBeat · Oct 5, 2026
Compugen Ltd. (CGEN) Discusses COM701 in Ovarian Cancer, MAIA Trial Preview, and UNIGEN Platform Advancements TranscriptSeeking Alpha · Oct 5, 2026
Compugen (NASDAQ:CGEN) versus MiMedx Group (NASDAQ:MDXG) Head-To-Head ComparisonDefense World · Sep 24, 2026
Compugen to Host Virtual KOL Event on COM701 in Ovarian Cancer & Unigen™ Platform Update on October 5, 2026PRNewsWire · Sep 22, 2026Compugen Ltd., an Israeli-based company established in 1993 and headquartered in Holon, is a clinical-stage enterprise focused on the discovery, development, and commercialization of therapeutic and product candidates. Its operations extend across Israel, the United States, and Europe. The company’s core activities center around its immuno-oncology pipeline, which includes several investigational treatments: COM701, an anti-PVRIG antibody currently undergoing Phase I clinical studies for solid tumors.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 3, 2026 | -$0.08 | -$0.07 | Beat |
| May 18, 2026 | -$0.07 | -$0.08 | Miss |
| Mar 2, 2026 | -$0.07 | $0.60 | Beat |
| Nov 10, 2025 | -$0.09 | -$0.07 | Beat |
| Aug 6, 2025 | -$0.07 | -$0.08 | Miss |
| May 19, 2025 | -$0.06 | -$0.08 | Miss |